HC Wainwright set a $3.00 price target on Vascular Biogenics (NASDAQ:VBLT) in a research report sent to investors on Thursday. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.
VBLT has been the subject of several other reports. Zacks Investment Research lowered shares of Vascular Biogenics from a hold rating to a sell rating in a report on Thursday, January 25th. ValuEngine lowered shares of Vascular Biogenics from a sell rating to a strong sell rating in a report on Friday, March 9th. Piper Jaffray Companies lowered shares of Vascular Biogenics from an overweight rating to a neutral rating and set a $4.00 target price for the company. in a report on Thursday, March 8th. Chardan Capital lowered shares of Vascular Biogenics from a buy rating to a neutral rating and reduced their target price for the stock from $25.00 to $3.00 in a report on Thursday, March 8th. Finally, JMP Securities lowered shares of Vascular Biogenics from an outperform rating to a market perform rating in a report on Thursday, March 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $3.19.
Shares of Vascular Biogenics stock opened at $2.38 on Thursday. Vascular Biogenics has a fifty-two week low of $2.20 and a fifty-two week high of $9.05.
Institutional investors and hedge funds have recently made changes to their positions in the business. ARK Investment Management LLC purchased a new stake in Vascular Biogenics during the 4th quarter valued at approximately $302,000. Alps Advisors Inc. purchased a new stake in Vascular Biogenics during the 4th quarter valued at approximately $234,000. IFP Advisors Inc grew its holdings in Vascular Biogenics by 339.7% during the 4th quarter. IFP Advisors Inc now owns 19,567 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 15,117 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Vascular Biogenics during the 3rd quarter valued at approximately $135,000. Finally, Raymond James & Associates grew its holdings in Vascular Biogenics by 71.5% during the 4th quarter. Raymond James & Associates now owns 55,466 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 23,124 shares in the last quarter. 5.61% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3298894/hc-wainwright-analysts-give-vascular-biogenics-vblt-a-3-00-price-target.html.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.